Anixa Biosciences (NASDAQ:ANIX – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.
Valuation and Earnings
This table compares Anixa Biosciences and Protalix BioTherapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anixa Biosciences | $210,000.00 | 432.02 | -$10.93 million | ($0.32) | -8.16 |
| Protalix BioTherapeutics | $80.62 million | 2.56 | $8.31 million | $0.23 | 11.13 |
Protalix BioTherapeutics has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Anixa Biosciences has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Anixa Biosciences and Protalix BioTherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anixa Biosciences | 1 | 1 | 3 | 0 | 2.40 |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
Anixa Biosciences currently has a consensus target price of $8.00, suggesting a potential upside of 206.51%. Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 368.75%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Anixa Biosciences.
Insider and Institutional Ownership
29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Anixa Biosciences and Protalix BioTherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anixa Biosciences | N/A | -76.59% | -67.80% |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
About Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
